Quick Comparison
| ALCAR | Emoxypine (Mexidol) | |
|---|---|---|
| Half-Life | 4-5 hours | 2-2.6 hours |
| Typical Dosage | Standard: 500-2000 mg daily in 1-2 doses. For cognitive support: 1000-2000 mg daily. For neuropathy: 1500-3000 mg daily. Take in the morning — may be mildly stimulating. | Standard: 125-375 mg daily in 2-3 divided doses. Commonly 125 mg twice daily. Take with food. Effects are noticeable within 30-60 minutes. Russian clinical practice uses 4-6 week courses. |
| Administration | Oral (capsules, powder). Well-absorbed on an empty stomach. | Oral (tablets). Also available as IV/IM injection in clinical settings. Mexidol is the brand name. |
| Research Papers | 9 papers | 10 papers |
| Categories |
Mechanism of Action
ALCAR
ALCAR crosses the blood-brain barrier via the organic cation transporter (OCTN2) more effectively than L-carnitine. In neurons, it is hydrolyzed by carnitine acetyltransferase to donate its acetyl group to coenzyme A, forming acetyl-CoA—which can then be used for acetylcholine synthesis via choline acetyltransferase, effectively providing raw material for the memory neurotransmitter. ALCAR also transports long-chain fatty acids across the inner mitochondrial membrane via the carnitine palmitoyltransferase system for beta-oxidation and ATP production. ALCAR activates nerve growth factor (NGF) signaling, possibly through modulation of NGF receptor (TrkA) expression or downstream MAPK/ERK pathways. It has antioxidant properties, reducing lipid peroxidation in mitochondrial membranes and scavenging free radicals. These mechanisms support cognitive function and neuroprotection.
Emoxypine (Mexidol)
Emoxypine (2-ethyl-6-methyl-3-hydroxypyridine succinate) has a 3-hydroxypyridine structure similar to vitamin B6 (pyridoxine). It is one of the most potent inhibitors of lipid peroxidation in brain tissue — it scavenges hydroxyl radicals and peroxyl radicals, inhibits Fe2+-induced lipid peroxidation, and may chelate transition metals. It modulates the GABA-benzodiazepine receptor complex (GABA-A), enhancing GABAergic transmission through positive allosteric modulation — possibly at a site distinct from the classical benzodiazepine binding site, explaining the lack of sedation and tolerance. It improves mitochondrial function (Complex I protection, membrane stabilization), stabilizes cell membranes (reducing fluidity changes during oxidative stress), and enhances cerebral microcirculation (possibly via nitric oxide or prostaglandin modulation). The anxiolytic mechanism may involve partial agonism or different subunit selectivity.
Risks & Safety
ALCAR
Common
Nausea, fishy body odor, restlessness, gastrointestinal discomfort.
Serious
May increase agitation in Alzheimer's patients. TMAO production may be a cardiovascular concern with chronic high doses.
Rare
Seizures in susceptible individuals, increased thyroid activity.
Emoxypine (Mexidol)
Common
Mild nausea, drowsiness, dry mouth.
Serious
Limited Western safety data. Allergic reactions reported.
Rare
Elevated blood pressure, emotional lability.
Full Profiles
ALCAR →
Acetyl-L-Carnitine is an acetylated form of L-Carnitine that crosses the blood-brain barrier more effectively than regular L-Carnitine. In the brain, it donates its acetyl group for acetylcholine synthesis and supports mitochondrial fatty acid oxidation for energy. Used clinically for age-related cognitive decline, depression, and diabetic neuropathy.
Emoxypine (Mexidol) →
A vitamin B6 derivative with powerful antioxidant and anxiolytic properties, widely prescribed in Russia and Eastern Europe for anxiety, cognitive impairment, and cerebrovascular disease. Emoxypine inhibits lipid peroxidation, modulates GABA-A and benzodiazepine binding sites, and improves cerebral blood flow. It provides anxiolytic effects similar to benzodiazepines without sedation, tolerance, or addiction.